Total revenue $418 million (exceeded high-end of guidance) Adj. EPS $0.63; down ($0.08) vs Q2'23 • Broad demand for Integra's diverse portfolio of leading brands • Continued successful market uptake of CereLink® monitors and microsensors Q2 2024 Earnings Presentation 2 IART Q2 2024 Earnings Presentation Non-GAAP Financial Measures INTEGRA _ July 29, 2024 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that ...

• Announced plans to focus relaunch of SurgiMend® and PriMatrix® at new state-of-the-art manufacturing facility in Braintree, Massachusetts, with operational readiness expected in the first-half of 2026. Advancing our Strategy including expectations concerning the Company's plans to implement a compliance master plan to improve the Company's quality system and GMP compliance and to operationalize the Company's Braintree facility and transition the manufacture of PriMatrix and SurgiMend to the Braintree faci ...

Second Quarter 2024 Highlights Second quarter GAAP earnings per diluted share of $(0.16), compared to $0.05 in the prior year; adjusted earnings per diluted share of $0.63, compared to $0.71 in the prior year. Announced plans to focus relaunch of SurgiMend® and PriMatrix® at new state-of-the-art manufacturing facility in Braintree, Massachusetts, with operational readiness expected in the first-half of 2026. Updating full-year 2024 revenue guidance to a range of $1.609 billion to $1.629 billion and adjusted ...

Second quarter GAAP earnings per diluted share of $(0.16), compared to $0.05 in the prior year; adjusted earnings per diluted share of $0.63, compared to $0.71 in the prior year. Second quarter revenues of $418.2 million increased 9.7% on a reported basis and 2.3% on an organic basis compared to the prior year. Revenue increased 0.3% on an organic basis excluding Boston. Received PMA approvable notification pending GMP certification for SurgiMend. Second Quarter 2024 Consolidated Performance Adjusted EBITDA ...

The earnings report, which is expected to be released on July 29, 2024, might help the stock move higher if these key numbers are better than expectations. On the other hand, if they miss, the stock may move lower. Zacks Consensus Estimate Investors should keep in mind that an aggregate change may not always reflect the direction of estimate revisions by each of the covering analysts. Estimate revisions ahead of a company's earnings release offer clues to the business conditions for the period whose results ...

Since receiving the third-party audit findings for its Boston manufacturing facility in March, Integra has been thoroughly reevaluating its plans and timeline to resume the manufacture of PriMatrix and SurgiMend at this site. Simultaneously, the Integra team has been furthering its plans to complete the construction and operationalization of the new state-of-the-art tissue manufacturing facility in Braintree. Based on these assessments, IART no longer intends to commence the manufacture of these products at ...

PRINCETON, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq: IART), a leading global medical technology company, is announcing its plans to restart the manufacture of PriMatrix® and SurgiMend® at its new manufacturing facility in Braintree, Massachusetts. The Company expects to operationalize this new facility in the first half of 2026. "Given the advantages of the Braintree facility and the challenges of the Boston facility, the decision to consolidate our efforts a ...

At Integra LifeSciences, we are driven by our purpose of restoring patients' lives. We innovate treatment pathways to advance patient outcomes and set new standards of surgical, neurologic, and regenerative care. We offer a comprehensive portfolio of high quality, leadership medical technology brands. For the latest news and information about Integra and its products, please visit www.integralife.com. Since receiving the third-party audit findings for its Boston, Massachusetts, manufacturing facility in Mar ...

A month has gone by since the last earnings report for Integra LifeSciences (IART) . Shares have added about 26% in that time frame, outperforming the S&P 500. Will the recent positive trend continue leading up to its next earnings release, or is Integra due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important catalysts. Integra's Q1 Earnings Match Estimates, Margins ...

Investors in Integra LifeScience Holdings Corporation (IART) need to pay close attention to the stock based on moves in the options market lately. That is because the Jun 21, 2024 $40.00 Call had some of the highest implied volatility of all equity options today. What is Implied Volatility? Implied volatility shows how much movement the market is expecting in the future. Options with high levels of implied volatility suggest that investors in the underlying stocks are expecting a big move in one direction o ...